Abu-Raddad EJ, Deeg MA, Fu H, Kelly RP, Pinaire JA, Tham LS. Single Doses of the Glucagon Receptor Antagonist LY2409021 Reduce Blood Glucose in Healthy Subjects and Patients with Type 2 Diabetes Mellitus (T2DM). 2011 American Diabetes Association (San Diego, CA).

Abu-Raddad EJ, Lim CN, Loh MT, Ng WT, Pinaire JA, Kelly RP, Tham LS. The Glucagon Receptor Antagonist LY2409021 Attenuates Increases in Hepatic Glucose Output (HGO) and Blood Glucose During Hyperglucagonemia in Healthy Male Subjects. 2011 American Diabetes Association (San Diego, CA) (President’s Poster Session)

Danny Soon. Can we Justify paying Volunteers for Research Participation. 3rd Asia Pacific Research Ethics Conference, 26th – 28th March 2014.

Danny Soon. The Effects of µ-opioid antagonism on insulin secretion in Type 2 Diabetes Patients. 5th Singapore Symposium on Metabolic Diseases, Singapore Bioimaging Consortium, 1st – 2nd August 2013.

Danny Soon. Risk-Benefit and Ethical Issues in Phase 1 and Non-Patient Volunteer Research. International Conference on Phase 1 and Early Phase Clinical Trials. The University of Hong Kong, April 26th 2013.

Danny Soon. Perspectives on Risk-Benefit in Non-Patient Volunteer Research. 2nd Asia Pacific Research Ethics Conference, 7th – 9th March 2012.